Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice

Aims: The tumour marker CA19-9 has been promoted as a reliable test for the detection of pancreatobiliary malignancy, yet its diagnostic role remains poorly defined. In this study the clinical interpretation of a raised serum CA19-9 level has been evaluated, with particular reference to obstructive...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2000-08, Vol.26 (5), p.474-479
Main Authors: Mann, DV, Edwards, R, Ho, S, Lau, WY, Glazer, G
Format: Article
Language:English
Subjects:
Adult
Aged
Analysis of Variance
Biliary Tract Neoplasms - blood
Biliary Tract Neoplasms - complications
Biliary Tract Neoplasms - diagnosis
Biliary Tract Neoplasms - immunology
Bilirubin - blood
Biological and medical sciences
Biomarkers, Tumor - blood
CA-19-9 Antigen - blood
Cholestasis - blood
Cholestasis - etiology
Cholestasis - immunology
Diagnosis, Differential
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
obstructive jaundice
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - complications
Pancreatic Neoplasms - diagnosis
Pancreatic Neoplasms - immunology
pancreatobiliary malignancy
Predictive Value of Tests
Tumors
tumour marker
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims: The tumour marker CA19-9 has been promoted as a reliable test for the detection of pancreatobiliary malignancy, yet its diagnostic role remains poorly defined. In this study the clinical interpretation of a raised serum CA19-9 level has been evaluated, with particular reference to obstructive jaundice. Methods: One hundred and sixty-four patients with a CA19-9 level above 33 U/ml were studied. Serum CA19-9 was compared with clinical diagnosis and correlated with serum bilirubin level. In a subgroup of jaundiced patients (16 benign and 15 malignant cases), follow-up CA19-9 levels were determined 2 weeks after biliary drainage. Results: The median CA19-9 level was lower in benign cases (102 (IQR 50–264) U/ml) than those with pancreatobiliary tumours (910 (IQR 263–6170) U/ml P
ISSN:0748-7983
1532-2157
DOI:10.1053/ejso.1999.0925